HUE028458T2 - Nagy affinitású anti-humán IgE antitestek - Google Patents
Nagy affinitású anti-humán IgE antitestek Download PDFInfo
- Publication number
- HUE028458T2 HUE028458T2 HUE11170255A HUE11170255A HUE028458T2 HU E028458 T2 HUE028458 T2 HU E028458T2 HU E11170255 A HUE11170255 A HU E11170255A HU E11170255 A HUE11170255 A HU E11170255A HU E028458 T2 HUE028458 T2 HU E028458T2
- Authority
- HU
- Hungary
- Prior art keywords
- antibody
- ser
- thr
- ige
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (8)
- Hagy aflmitásü ami-lmmán IgB andtextek Szabadalmi igénypontok L Egy izolált antitest vagy égy műgé&*MtÓ íragme-nse, moly egy CDRLI-t, CDRL2-Í, és 'CDRL3-1 tartalmazó variábilis könnyű lánc régiót és egy CDRH Ut» CDRH2-A, és CDRH3R tartalmazó variábilis nehéz lánc régiét tartalmaz, aboi CDRL! az 5. számú szekvenciának megfeleld ami»o$av*zekvenciábői, CDRL2 a 8. számú szekvenciának megfelelő amitmsavszekveneiáboE €DRi,3 a QQSWSWPTT amlnosavszekvenclábóE CDRH1 a El számé szekvenciának megfelelő aminosavszekvenciából, CDRH2 a 25. számú szekvenciának megfelelő annoosavszckveneiábéE és CDRH3 a 26. szánra szekvenciának megfelelő rnninosavszckvendáből áll, almi az antitest vagy antigén-kötő fragmente specifikusa». kötődik az, IgE-hez.
- 2. Az. E igénypont szerinti antitest vagy antigén-kötő íragmense, almi a variábilis könnyű lánc régié a 63,. szántó szekvenciának megfelelő- aminosavszekvenciát tartalmazza, vagy ahol a. variábilis nehéz lánc régió a 64. számé szekvenciának megfelelő anűnos-avszekvenclát tartalmazza.
- 3. Az E vagy 2, igénypont szerinti antitest vagy antigén-kötő íragmense, áltól a variábilis könnyű lánc régió a 63. számú szekvenciának" Megfeleld amlnoSávszekvcnciátó, és a variábilis nehéz lánc .régié a 64. számú szekvenciának megfelelő amínosavszekveneiájű.
- 4. Az 1-3. igénypontok bármelyike szerinti antitest vagy antigén-kötö íragmense, aboi az antitest vagy az amigén-kekö fragmense tartalmaz továbbá, egy állandó könnyű lánc régiót és egy állandó nebéz lánc régiét, 5. A 4. igénypont szerinti antitest vagy antigén-kötő fragmense, ahol az állandó könnyű, lánc régió az 5$. szánté szekvenciának megfelelő amtnosavszekvenciával és az állandó nehéz lánc régió a 60. számú szekvenciának megfelelő aminosavszekverteiáv a! rendelkezik. & Az 1-5. igénypontok bármelyike szerinti antitest vagy antigén-kötő fmgmense, mely továbbá egy jelzőhöz, van kapcsolva. ?.. Készítmény, mois az 1-5. igénypontok bármelyike szerinti antitest vagy antigén-kötő feigmensének terápiásán hatásos mennyiségét, sis egy gyógyszerészetíleg elfogadható hordozót tartalmaz. S, Diagnosztikai kit, mely az !»6, igéítypoaták bármelyike szerinti antitestet vagy aniigén-kötő ffagmensvt tartalmazza,
- 9. Eljárás alanyban az IgE-szim mérésére, melynek során az alanyból veit mintái, mely minta IgE molekulákat tartalmaz, az 1-6, igénypontok bármelyike szerinti antitesttel vagy .antigén-kötő íragmensével erintkeztetjük; és megállapítják az antitest vagy antigén-kőto tragmense reteneiójának mértékét egy kontroll alanyból vett kontroll mintához viszonyítva, ahol az antitest vagy antigén-kötő íragmemse relenciójának kontroli alanyból vett kontroll mintához viszonyított alacsonyabb vagy magasabb mértéke jelzi, hogy az alany a kőmtől! alanyhoz viszonyává magasabb vagy alacsonyabb IgE molekula szinttel rendelkezik.
- 10. Eljárás alanyban abnormális IgE szinttel összefüggő rendellenesség diagnosztizálására, melynek során az alanyból vett mintát, mely minta IgE molekulákat tartalmaz, az l-ó. igénypontok bármelyike szerinti antitesttel vagy antigén-kötő íragmensével árintkeztetjilk; és megállapítjuk az antitest vagy antigén-kötő fragm.en.se relációjának mértékét egy kontroll alanyból vett kontroll mintához viszonyítva, aboi az antitest vagy antigén-kötő fetgmense retenoié-jának kontroll alanyból vett kontroll mintához viszonyított alacsonyabb vagy magasabb mértéke jelzi, hogy az alany abnormális IgE szinttel összefüggő betegségben szenved. ! I, Az. !-Í. igénypontok bármelyike szerinti egy alany abnormálisán magas IgE szintté! ösz-szefüggö betegségének kezelést eljárásában történő alkalmazásra.
- 12. A lö. igénypont szerinti eljárás vagy az antitest vagy antigén-kötő tragmense a 11, igénypont szerinti alkalmazásra, ahol a betegség asztma, allergiás rhinitis, ekcéma, urticaria, atopiás demmtitis, vagy élelmi szerallargta,
- 13. Vektor, mely az .146, igénypontok bármelyike szerinti antitestet vagy «migén-kdtö fragmensét kódold nukleiösavat tartalmaz, 14. A 13. igénypont szeriét! vektort tartalmazd soft. 15. A 14. igénypont szerinti sejt, ahol a sejt. ATCC P?A«$680 deponálási szánni.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44422903P | 2003-02-01 | 2003-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE028458T2 true HUE028458T2 (hu) | 2016-12-28 |
Family
ID=32850839
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE08104978A HUE028407T2 (hu) | 2003-02-01 | 2004-02-02 | Nagy affinitással rendelkezõ humán IgE antitestek |
| HUE11170255A HUE028458T2 (hu) | 2003-02-01 | 2004-02-02 | Nagy affinitású anti-humán IgE antitestek |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE08104978A HUE028407T2 (hu) | 2003-02-01 | 2004-02-02 | Nagy affinitással rendelkezõ humán IgE antitestek |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US7531169B2 (hu) |
| EP (4) | EP2000481B1 (hu) |
| JP (4) | JP2006516408A (hu) |
| CN (3) | CN1829806A (hu) |
| AU (3) | AU2004209637A1 (hu) |
| CA (2) | CA2514839A1 (hu) |
| CY (2) | CY1118063T1 (hu) |
| DK (2) | DK2000481T3 (hu) |
| ES (2) | ES2575547T3 (hu) |
| HK (3) | HK1085771A1 (hu) |
| HU (2) | HUE028407T2 (hu) |
| IL (1) | IL176940A (hu) |
| MX (1) | MX338940B (hu) |
| PT (1) | PT2000481E (hu) |
| SI (2) | SI2000481T1 (hu) |
| WO (2) | WO2004070010A2 (hu) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060234296A1 (en) * | 2003-02-01 | 2006-10-19 | Sanjaya Singh | Method for generating high affinity antibodies |
| DK2000481T3 (en) * | 2003-02-01 | 2016-06-06 | Tanox Inc | High affinity anti-human IgE antibodies |
| DK1711528T3 (da) | 2003-12-23 | 2012-08-20 | Genentech Inc | Behandling af cancer med hidtil ukendte anti-il 13 monoklonale antistoffer |
| KR20070008578A (ko) * | 2004-02-02 | 2007-01-17 | 타녹스 인코퍼레이티드 | 신규한 ＩｇＥ 에피토프의 확인 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2006055704A2 (en) * | 2004-11-17 | 2006-05-26 | Curagen Corporation | Antibodies directed to ten-m proteins and uses thereof |
| JP5389442B2 (ja) * | 2005-09-29 | 2014-01-15 | メディミューン，エルエルシー | 膜Ｉｇ特異的抗体を同定する方法および免疫グロブリンを生成する前駆体細胞を標的化するための使用 |
| AR065368A1 (es) | 2007-02-15 | 2009-06-03 | Astrazeneca Ab | Anticuerpos para moleculas de ige |
| PT2132230E (pt) * | 2007-03-22 | 2014-07-17 | Genentech Inc | Anticorpos apoptóticos anti-ige que se ligam ao ige ligado a membrana |
| DE102007052281A1 (de) * | 2007-11-02 | 2009-05-07 | Zenteris Gmbh | Einschritt-Multiplex-Immuntest |
| CN101883862A (zh) | 2007-12-03 | 2010-11-10 | 爱德芳世株式会社 | 抗体制备方法 |
| US20130338038A1 (en) | 2007-12-21 | 2013-12-19 | Pdl Biopharma, Inc. | Method of screening complex protein libraries to identify altered properties |
| CN101230103B (zh) * | 2008-03-25 | 2011-09-07 | 中国医药集团总公司四川抗菌素工业研究所 | 一全人源重组抗-IgE抗体 |
| DK2853545T3 (en) | 2008-09-17 | 2016-08-29 | Xencor Inc | Antibody specific for IgE |
| US9187568B2 (en) | 2009-05-07 | 2015-11-17 | Stallergenes S.A. | Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route |
| CN102695956B (zh) | 2009-10-26 | 2015-12-09 | 基因泰克公司 | 用于检测对治疗性抗IgE抗体特异性的抗体的测定法及其在过敏反应中的用途 |
| SG184473A1 (en) * | 2010-04-07 | 2012-11-29 | Abbvie Inc | Tnf-alpha binding proteins |
| AR089434A1 (es) | 2011-12-23 | 2014-08-20 | Genentech Inc | Procedimiento para preparar formulaciones con alta concentracion de proteinas |
| AR091305A1 (es) | 2012-01-31 | 2015-01-28 | Genentech Inc | ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO |
| KR102201607B1 (ko) | 2012-05-18 | 2021-01-12 | 제넨테크, 인크. | 고농도 모노클로날 항체 제제 |
| AR092177A1 (es) | 2012-08-21 | 2015-03-25 | Sanofi Sa | Metodos para tratar o prevenir asma administrando un antagonista de il-4r |
| TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法 |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| WO2015013668A1 (en) * | 2013-07-26 | 2015-01-29 | Ke Zhang | Anti-immunoglobulin e antibodies and methods of use thereof |
| US10458984B2 (en) | 2014-01-29 | 2019-10-29 | Ge Healthcare Bio-Sciences Ab | Method and system for interaction analysis |
| KR20160120735A (ko) | 2014-02-28 | 2016-10-18 | 리제너론 파아마슈티컬스, 인크. | Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 |
| ES2811303T3 (es) * | 2014-06-17 | 2021-03-11 | Academia Sinica | Anticuerpos anti-IGE humanizados que entrecruzan CD23 en linfocitos B pero no sensibilizan los mastocitos |
| WO2016062734A1 (en) * | 2014-10-24 | 2016-04-28 | F. Hoffmann-La Roche Ag | Vh-vl-interdomain angle based antibody humanization |
| KR20170081262A (ko) | 2014-11-14 | 2017-07-11 | 사노피 바이오테크놀로지 | Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법 |
| WO2018045130A1 (en) | 2016-09-01 | 2018-03-08 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| BR112019012686A2 (pt) | 2016-12-22 | 2019-11-19 | Genentech Inc | métodos e formulações para a redução do tempo de reconstituição de polipeptídeos liofilizados |
| AU2018205484A1 (en) | 2017-01-06 | 2019-08-01 | Sixal, Inc. | Therapeutic anti-lgE antibodies and methods and compositions thereof |
| WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
| PT3515465T (pt) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r |
| KR20200081429A (ko) | 2017-10-30 | 2020-07-07 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| AU2019218128A1 (en) | 2018-02-09 | 2020-09-17 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
| EP3773904A1 (en) | 2018-03-26 | 2021-02-17 | Novartis AG | Methods of treating chronic spontaneous urticaria using ligelizumab |
| US11292847B2 (en) | 2018-05-13 | 2022-04-05 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an IL-4R inhibitor |
| CN109651510B (zh) * | 2018-12-04 | 2023-03-24 | 上海长征医院 | 抗Eno1抗体及其用途 |
| CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| CA3147068A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
| JP2021141861A (ja) * | 2020-03-13 | 2021-09-24 | 富士フイルム和光純薬株式会社 | 抗原に対する親和力が向上した抗体のスクリーニング方法および製造方法 |
| WO2021255621A1 (en) | 2020-06-15 | 2021-12-23 | Novartis Ag | Treatment of food allergy using anti-ige antibodies |
| KR20240021856A (ko) | 2021-06-14 | 2024-02-19 | 노파르티스 아게 | 항-IgE 항체를 함유하는 약제학적 제형 |
| WO2023111811A1 (en) | 2021-12-14 | 2023-06-22 | Novartis Ag | Treatment of allergic reactions using anti-ige antibodies |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268176A (en) * | 1916-11-29 | 1918-06-04 | Us Slicing Machine Co | Power mechanism for slicing-machines. |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5428133A (en) | 1987-12-31 | 1995-06-27 | Tanox Biosystems, Inc. | Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils |
| US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
| US5614611A (en) | 1987-12-31 | 1997-03-25 | Tanox Biosystems, Inc. | Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils |
| US5449760A (en) | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
| DE122006000007I1 (de) | 1987-12-31 | 2006-04-27 | Tanox Biosystems Inc | Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden. |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| IL94611A (en) | 1989-06-05 | 1994-12-29 | Organogenesis Inc | Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| DK0564531T3 (da) * | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| WO1992017207A1 (en) * | 1991-03-26 | 1992-10-15 | Tanox Biosystems, Inc. | MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS |
| EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
| AU687755B2 (en) | 1992-08-21 | 1998-03-05 | Genentech Inc. | Method for treating an LFA-1-mediated disorder |
| DE69333484T2 (de) * | 1992-09-24 | 2005-03-24 | Novartis Ag | Umgestaltete monoklonale Antikörper gegen ein Immunglobulinisotyp |
| US5958708A (en) * | 1992-09-25 | 1999-09-28 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US6066718A (en) * | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| PL174721B1 (pl) | 1992-11-13 | 1998-09-30 | Idec Pharma Corp | Przeciwciało monoklonalne anty-CD20 |
| US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| WO1999038531A1 (en) * | 1998-01-29 | 1999-08-05 | Tanox, Inc. | TREATING ATOPIC DERMATITIS WITH IgE ANTAGONISTS |
| US6299875B1 (en) | 1998-06-04 | 2001-10-09 | Panacea Pharmaceuticals, Llc | Methods to block IGE binding to cell surface receptors of mast cells |
| DK2000481T3 (en) * | 2003-02-01 | 2016-06-06 | Tanox Inc | High affinity anti-human IgE antibodies |
| US20050169909A1 (en) | 2004-02-02 | 2005-08-04 | Sanjaya Singh | Identification of novel IgE epitopes |
| US20060234296A1 (en) | 2003-02-01 | 2006-10-19 | Sanjaya Singh | Method for generating high affinity antibodies |
-
2004
- 2004-02-02 DK DK08104978.5T patent/DK2000481T3/en active
- 2004-02-02 WO PCT/US2004/002892 patent/WO2004070010A2/en active Application Filing
- 2004-02-02 ES ES08104978.5T patent/ES2575547T3/es not_active Expired - Lifetime
- 2004-02-02 DK DK11170255.1T patent/DK2407485T3/en active
- 2004-02-02 CA CA002514839A patent/CA2514839A1/en not_active Abandoned
- 2004-02-02 ES ES11170255.1T patent/ES2566778T3/es not_active Expired - Lifetime
- 2004-02-02 EP EP08104978.5A patent/EP2000481B1/en not_active Expired - Lifetime
- 2004-02-02 HU HUE08104978A patent/HUE028407T2/hu unknown
- 2004-02-02 PT PT08104978T patent/PT2000481E/pt unknown
- 2004-02-02 AU AU2004209637A patent/AU2004209637A1/en not_active Abandoned
- 2004-02-02 EP EP04707380A patent/EP1592777A4/en not_active Withdrawn
- 2004-02-02 CN CNA2004800082701A patent/CN1829806A/zh active Pending
- 2004-02-02 AU AU2004209638A patent/AU2004209638B2/en not_active Expired
- 2004-02-02 WO PCT/US2004/002894 patent/WO2004070011A2/en active Application Filing
- 2004-02-02 HU HUE11170255A patent/HUE028458T2/hu unknown
- 2004-02-02 CA CA2514840A patent/CA2514840C/en not_active Expired - Lifetime
- 2004-02-02 US US10/544,056 patent/US7531169B2/en not_active Expired - Lifetime
- 2004-02-02 EP EP04707368A patent/EP1592776A4/en not_active Withdrawn
- 2004-02-02 CN CN201210316908.4A patent/CN102993306B/zh not_active Expired - Lifetime
- 2004-02-02 SI SI200432324A patent/SI2000481T1/sl unknown
- 2004-02-02 JP JP2006503243A patent/JP2006516408A/ja active Pending
- 2004-02-02 EP EP11170255.1A patent/EP2407485B1/en not_active Expired - Lifetime
- 2004-02-02 SI SI200432311A patent/SI2407485T1/sl unknown
- 2004-02-02 CN CN2004800070117A patent/CN1771338B/zh not_active Expired - Lifetime
- 2004-02-02 JP JP2006503245A patent/JP4764334B2/ja not_active Expired - Lifetime
- 2004-07-29 MX MX2011007343A patent/MX338940B/es unknown
-
2006
- 2006-07-17 HK HK06107957.0A patent/HK1085771A1/xx not_active IP Right Cessation
- 2006-07-18 IL IL176940A patent/IL176940A/en active IP Right Grant
-
2009
- 2009-03-27 US US12/413,014 patent/US8252284B2/en active Active
- 2009-06-01 HK HK09104910.0A patent/HK1126788A1/zh not_active IP Right Cessation
-
2010
- 2010-09-09 JP JP2010202452A patent/JP2011042654A/ja active Pending
-
2011
- 2011-04-26 JP JP2011098737A patent/JP5296138B2/ja not_active Expired - Lifetime
- 2011-05-03 AU AU2011202021A patent/AU2011202021B2/en not_active Expired
-
2012
- 2012-07-17 HK HK12106994.9A patent/HK1166330A1/zh not_active IP Right Cessation
- 2012-07-27 US US13/559,938 patent/US8604171B2/en not_active Expired - Lifetime
-
2013
- 2013-11-07 US US14/074,309 patent/US9156908B2/en active Active
-
2016
- 2016-04-04 CY CY20161100269T patent/CY1118063T1/el unknown
- 2016-06-09 CY CY20161100504T patent/CY1117617T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2000481T3 (en) | High affinity anti-human IgE antibodies | |
| AU2009202408A1 (en) | Identification of novel IgE epitopes | |
| US20110200604A1 (en) | IDENTIFICATION OF NOVEL IgE EPITOPES | |
| US20060234296A1 (en) | Method for generating high affinity antibodies | |
| AU2012261739A1 (en) | Identification of novel IgE epitopes | |
| AU2013263817A1 (en) | High affinity anti-human IgE antibodies |